SEC For	m 4																	
FORM 4 UNI			UNITED	JNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549												OMB APPROVAL		
Section 16. Form 4 or Form 5 obligations may continue. See					ENT OF CHANGES IN BENEFICIAL OWNERSHIP ed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									OMB Number: 3235-0287   Estimated average burden    hours per response: 0.5				
1. Name and Address of Reporting Person <sup>*</sup> Oliveto Joseph					2. Issuer Name and Ticker or Trading Symbol <u>Milestone Pharmaceuticals Inc.</u> [ MIST ]								k all applica Director	ble)	10% Own		ner	
(Last)(First)(Middle)C/O MILESTONE PHARMACEUTICALS INC.1111 DR. FREDERIK-PHILIPS BLVD, STE 420					3. Date of Earliest Transaction (Month/Day/Year) 12/21/2019								below)	resident and CEO				
(Street) MONTR?AL A8 H4M 2X6					4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Indivi Line) X								vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(5	State)	(Zip) able I - Nor	-Deriv	ative S	ecuritie	es Arr	wired	Dis	nosed of	f or Ben	eficially	Owned					
1. Title of Security (Instr. 3) Date						2A. Deer Execution if any (Month/E	med on Date,	ate, 3. Code (Inst		4. Securiti	ies Acquire		5. Amount Securities Beneficial Owned Fo	Form Iy (D) o		Direct Ir Indirect B str. 4) C	7. Nature of Indirect Beneficial Ownership	
							Code	v	Amount	(A) or (D)	Price	Reported Transactio (Instr. 3 ar	n(s) 1d 4)		(	Instr. 4)		
Common Shares 12/21					/2019			М		7,400 A		\$1.54	280,555			D		
			Table II - I							osed of, onvertib			wned					
1. Title of Derivative Security (Instr. 3)	ivative Conversion Date urity or Exercise (Month/Day/Year		3A. Deemed Execution Dat if any (Month/Day/Ye	Cod	saction e (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisabl Expiration Date (Month/Day/Year)		e	of Securities		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Cod	e V	V (A)		Date Exercisa	ble	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)				
Employee Stock Option (right to buy)	\$1.54	12/21/2019		М			7,400	(1)		12/12/2027	Common Shares	7,400	\$0.00	113,8	56	D		
Employee Stock Option (right to buy)	\$3.74	06/05/2020		A		150,000		(2)		06/05/2030	Common Shares	150,000	\$0.00	150,00	00	D		

Explanation of Responses:

1. The original grant was for 252,853 option shares. Twenty-five percent (25%) of the shares subject to the option vested on September 19, 2017, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

2. The shares subject to this option shall vest in twenty-four (24) equal monthly installments commencing on July 5, 2020, subject to the recipient continuing to provide service to the Issuer through each such date. **Remarks:** 

## /s/ Eric Popp, Attorney-in-Fact 06/08/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.